Patrick Campbell

Results of a meta-analysis of more than 2 dozen studies indicate DCB treatment may actually reduce mortality risk long-term.

A new analysis has found that low blood pressure in older, frail adults could increase mortality risk as much as 63%.

Osilodrostat oral tablets are indicated for the treatment of Cushing's disease in patients not eligible for surgery or in those who still have surgery despite the disease.

A study from EPI Scientific Sessions 2020 is shedding light on the prevalence of certain risk factors among black ethnic groups compared to their white counterparts.

New data from a team of European investigators suggest Neurologic Music Therapy could have benefits for patients recovering from a stroke event.

New data from Kaiser Permanente Northern California is quantifying just how much of an impact adherence to each additional guideline can impact patients following AMI.

With approval, the new implant becomes the first approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.

Part 1 of the feature series includes a conversation with Anna Lembke, MD, on the most impactful players and products of the 30-year crisis.

A new study is diving into differences in long-term outcomes, including remission rates and weight loss, seen among patients undergoing RYGB and SG.

A Mayo Clinic analysis is shedding light on the real-world success of ablation in lowering risk of mortality and HF hospitalizations.

New data from EPI Lifestyle Conference 2020 is shedding light on the impact of initiating estradiol therapy closer to the onset of menopause.

An analysis of 180,000 patients in South Korea is shedding new light on the potential poor oral hygiene can have on a person's risk of diabetes.

Approval of isatuximab-irfc (Sarclisa) was based on the results of a 307-person trial, according to a statement from the FDA.

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.

Analysis of more than 13k patients from Taiwan found a vegetarian diet was linked to a lower risk of incident stroke events later in life.

Sika Dunyoh, director of education programs with NORD, discusses that year in rare disease and what to expect moving forward.

A new study examines how different types of chronic conditions were associated with different increases in risk of visual impairment.

A discussion on how to approach the real-world application of bempedoic acid with the Chief of Cardiology at Baylor College of Medicine.

The non-statin, fixed-dose combination therapy received approval less than one week after bempedoic acid received approval for treatment of HeFH.

The approval is the second non-statin LDL-C lowering therapy from Esperion to receive approval in the month of February.

Early menopause onset has been linked to increased CVD risk, but a new study from England is examining whether age of onset has a role in worsening risk factors.

The VistaScan mobile ultrasound platform from Emagine Solutions Technology can be used via an app and connect directly to a clinician's cell phone or tablet.

Results of the LINK-HF study indicate a wearable sensors from Vital Connect combined with a predictive algorithm can predict HF exacerbations.

The FDA announced the first approval of ProAir HFA—1 of the most popular inhalers in the US market.

New data from a study of 30 patients found specific characteristics of gut microbiota could predict the presence of pulmonary hypertension with greater than 80% accuracy.

With approval, the GLP-1 receptor agonist becomes the first diabetes drug approved for reducing MACE in patients with and without established cardiovascular.

The approval of bempedoic acid (Nexletol) marks the first oral, non-statin therapy approved by the FDA as a lipid-lowering agent in nearly 20 years.

The Novalung System is the first ECMO device approved for use for more than 6 hours.

Clinical trial data for the lipid-lowering non-statin agent indicates it can lower LDL-C by as much as 18% when combined with maximally tolerated statins.

A secondary analysis of patients with prior stroke, TIA, or thromboembolism from AUGUSTUS is revealing more about the use of apixaban in patients with AFib.